The transaction will be financed through a combination of cash on hand and a revolving line of credit facility that Bio-Techne expects to obtain prior to the closing of the acquisition.
The partnership with Exosome Diagnostics is part of CareFirst's HealthWorx program, under which the insurance provider works with early-stage companies to accelerate health plan coverage of their products.